Study to Evaluate the Efficacy Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)

  • End date
    Jun 25, 2022
  • participants needed
  • sponsor
    Urovant Sciences GmbH
Updated on 28 February 2021
benign prostatic hypertrophy
alpha blocker
micturition chart


This study will assess the efficacy of vibegron compared with placebo in men with overactive bladder (OAB) symptoms on pharmacological therapy for benign prostatic hyperplasia (BPH) as defined by micturition and urgency episodes.

Condition bladder disorder, Overactive Bladder, Bladder Disorders
Treatment Placebo, vibegron
Clinical Study IdentifierNCT03902080
SponsorUrovant Sciences GmbH
Last Modified on28 February 2021


Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 45 yrs?
Are you male?
Do you have any of these conditions: Bladder Disorders or bladder disorder or Overactive Bladder?
Do you have any of these conditions: bladder disorder or Bladder Disorders or Overactive Bladder?
Do you have any of these conditions: bladder disorder or Overactive Bladder or Bladder Disorders?
Do you have any of these conditions: Overactive Bladder or bladder disorder or Bladder Disorders?
Do you have any of these conditions: Bladder Disorders or Overactive Bladder or bladder disorder?
Participant should have been on and agree to continue to stay on a stable dose of benign prostatic hyperplasia (BPH) treatment with either a) alpha blocker monotherapy or b) alpha blocker + 5 alpha reductase inhibitor
Participant has an International Prostate Symptom Score total score of 8
Participant has a prostate-specific antigen level < 4 nanograms per milliliter (ng/mL), or if 4 ng/mL but 10 ng/mL, prostate cancer has been ruled out to the satisfaction of the investigator
Participant must have both additional qualifications based on the 3-day Bladder Diary period: a) having an average of 8 but 20 micturition episodes per day over the 3-day diary period, and (b) having an average of 3 urgency episodes per day over the 3-day diary period
Participant must have a post void residual volume value of < 100 mL
Having at least 2 average nocturia episodes per night based on 3-day Bladder Diary at baseline. Nocturia is defined as waking to pass urine during the main sleep period

Exclusion Criteria

Participant has a history of 24-hour urine volume greater than 3,000 mL
Has lower urinary tract pathology that could, in the opinion of the investigator, be responsible for urgency, frequency, or incontinence
Has a history of prostate surgery, including minimally invasive transurethral or transrectal procedures, procedural treatments for BPH within 6 months of Screening or has a planned prostate surgery
Has a history of urinary retention requiring an intervention (e.g., catheterization) for any reason
Has maximum urinary flow (Qmax) < 5.0 mL/second with a minimum voided volume of 125 mL
Has a history of or current nocturnal polyuria
Has an active or recurrent (> 3 episodes per year) urinary tract infection by clinical symptoms or laboratory criteria ( 5 white blood cells/high power field [hpf] with presence of red blood cell [RBC] and/or a positive urine culture, defined as 10^5 colony forming units (CFU)/mL (i.e., 100 10^3 CFU/mL in a single specimen)
Has uncontrolled hyperglycemia (defined as fasting blood glucose > 150 milligrams per deciliter (mg/dL) or 8.33 millimoles per liter (mmol/L) or non-fasting blood glucose > 200 mg/dL or 11.1 mmol/L) or, if in the opinion of the investigator, is uncontrolled
Has uncontrolled hypertension (systolic blood pressure of 180 millimeters of mercury (mmHg) and/or diastolic blood pressure of 100 mmHg) or has a resting heart rate (by pulse) > 100 beats per minute (min)
Has a history of cerebral vascular accident, transient ischemic attack, unstable angina, myocardial infarction, coronary artery interventions (e.g., coronary artery bypass grafting or percutaneous coronary interventions [e.g., angioplasty, stent insertion]), or neurovascular interventions (e.g., carotid artery stenting) within 6 months prior to the Screening Visit
Has alanine aminotransferase or aspartate aminotransferase > 2.0 times the upper limit of normal (ULN), or bilirubin (total bilirubin) > 1.5 ULN (or > 2.0 ULN if secondary to Gilbert syndrome or pattern consistent with Gilbert syndrome)
Has an estimated glomerular filtration rate < 30 mL/min/1.73 meters squared (m^2)
Has a history or current evidence of any condition, therapy, laboratory abnormality, or other circumstances that might, in the opinion of the investigator, confound the results of the study, interfere with the participant's ability to comply with the study procedure, or make participation in the study not in the participant's best interest
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note